All Tox In Focus volumes
Tox In Focus
|
Focused Clinical Reference
Vol. 23  ·  Antidepressants (SSRIs and SNRIs)  ·  July 2026
ANTIDEPRESSANTS
Adherence monitoring, CYP interactions, and the false positives they trigger

Antidepressant monitoring by LC-MS/MS confirms adherence to SSRIs (citalopram, fluoxetine, paroxetine, sertraline), SNRIs (duloxetine, venlafaxine), and related agents (bupropion, trazodone). Several of these are also common causes of false positives on immunoassay screens, so they matter for interpretation as well as adherence.1

Why This Matters Now

These antidepressants are among the most-prescribed medications, and several are documented immunoassay false-positive triggers: bupropion and trazodone can cause amphetamine false positives, and venlafaxine can cause PCP false positives. A specific LC-MS/MS result resolves both adherence questions and screen discrepancies.3

⚠ When an amphetamine or PCP immunoassay is unexpectedly positive in a patient on bupropion, trazodone, or venlafaxine, suspect cross-reactivity and confirm by LC-MS/MS.
Clinical Presentation
TOXICITY
Serotonin toxicity with serotonergic combinations
Seizures (bupropion overdose)
QT effects (citalopram, high dose)
Sedation (trazodone)
Nausea, tremor
DISCONTINUATION
Discontinuation syndrome on abrupt stop
Dizziness, 'brain zaps'
Flu-like symptoms, nausea
Insomnia, irritability
Worse with short half-life agents (paroxetine, venlafaxine)
Important: Combining serotonergic antidepressants with other serotonergic agents (some opioids, MAOIs, linezolid) risks serotonin toxicity. CYP2D6-inhibiting antidepressants (fluoxetine, paroxetine, duloxetine) can raise levels of co-prescribed drugs and reduce the efficacy of prodrugs such as tramadol and codeine.
UDT Considerations

LC-MS/MS measures the specific antidepressant and, where relevant, its metabolite (e.g., norfluoxetine, desmethylvenlafaxine). Absence in a prescribed patient may reflect non-adherence, PRN use, a drug interaction, or altered CYP metabolism. Because several of these agents cross-react on immunoassays, use definitive testing to distinguish true amphetamine or PCP exposure from an antidepressant-driven false positive.3

Clinical Guidance
  • Order specific LC-MS/MS to confirm adherence; there is no antidepressant immunoassay.1
  • When an amphetamine or PCP screen is unexpectedly positive, check for bupropion, trazodone, or venlafaxine and confirm by LC-MS/MS.3
  • Interpret an unexpected negative in a prescribed patient as possible non-adherence, PRN use, or altered CYP metabolism.
  • Account for CYP2D6 inhibitors (fluoxetine, paroxetine, duloxetine) that can reduce tramadol/codeine efficacy or raise other drug levels.2
  • Consider genetic and drug-interaction effects on measured levels before concluding non-adherence.
Point-of-Care Testing Availability
Available strips
No point-of-care strip detects specific antidepressants.
Clinical use
But several antidepressants trigger false positives on other immunoassays.
Limitations
LC-MS/MS confirms the specific antidepressant and metabolite.
ANTIDEPRESSANTS  |  Clinical & Program Guidance
Tox In Focus Vol. 23  ·  July 2026  ·  Page 2 of 2
Interpreting the Test Result
▲  If Testing Is Positive

Confirms recent use. Detection indicates use within the estimated window; levels do not confirm dose or schedule adherence.

Explains some screen positives. An antidepressant-positive result can account for an amphetamine or PCP immunoassay false positive.3

Metabolite supports ingestion. Where measured (norfluoxetine, desmethylvenlafaxine), the metabolite supports genuine use.

Analytes and Estimated Urine Detection Windows
AntidepressantUrine analyte(s)Estimated window
FluoxetineFluoxetine, norfluoxetineParent 5-15 d (acute) to 20-30 d (chronic); norfluoxetine 20-80 d
SertralineSertraline4-8 days
Citalopram / escitalopram+ N-desmethyl-citalopram5-8 days
ParoxetineParoxetine4-6 days
Venlafaxine+ desmethylvenlafaxineParent 1.5-2 d; metabolite 2-3 d
DuloxetineDuloxetine2-4 days
BupropionHydroxybupropionUp to 5 days
TrazodoneTrazodoneUp to 3 days

Windows are estimated from half-life (about 5x t-half) and vary widely; fluoxetine and its long-lived metabolite norfluoxetine persist longest.

Key References
  1. O'Donnell JM, Bies RR, Shelton RC. Drug therapy of depression and anxiety disorders. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw Hill; 2017.
  2. Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533-544.
  3. Reisfield GM, Goldberger BA, Bertholf RL. 'False-positive' and 'false-negative' test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952.
DISCLAIMER: This document is intended for clinical reference and educational purposes only. It does not constitute medical, legal, or professional advice and should not replace independent clinical or programmatic judgment. Content reflects published data available at time of preparation. ToxiPharm LLC makes no warranties regarding completeness or applicability in all settings.  |   © 2026 ToxiPharm LLC  |  toxipharm.org
Back to Tox In Focus ToxiPharm home →